Florence Séjourné

Florence Séjourné

Florence Séjourné

CEO DA VOLTERRA & President BEAM Alliance - Paris - France

Florence Séjourné is the chief executive officer of DA VOLTERRA, a Paris-based biotech company that develops innovative products for the protection of the microbiota from antibiotic residues for which the medical need is increasing. Its most advanced product, DAV132, is a novel and unique oral phase 2 stage-product designed to fight the damaging effects of antibiotics on the large intestine.
Prior to joining Da Volterra in 2008, Florence spent 11 years co-founding and developing Genfit (Euronext GNFT), now a leading public European biotech company in the field of metabolic and inflammatory diseases with a particular focus on liver and GI (NASH). Florence has thus the experience of successful entrepreneurial adventures and the capacity to set up and lead a highly professional organization from early research drug discovery to late-stage clinical development and market access.
Florence was trained in France (Mines Paritech, Biotechnology Major) and holds an MS in Pharmaceutics & Bioengineering from the University of Illinois at Chicago.

Encouraged by Da Volterra’s founder Prof Antoine Andremont, well-known opinion leader in the field of antimicrobial resistance, Florence has been active in contributing to discussions in various groups mostly in Europe and in the USA these last years on creative business models and incentives to face the economic issues of innovation in the antimicrobial resistance (AMR) and bacterial infections. As Da Volterra’s CEO, she initiated the BEAM Alliance, which represents more 50 European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance from 14 countries. The BEAM Alliance objectives are to collaborate with the existing community of stakeholders dedicated to implementing tangible strategies and give its members a unique voice as small & medium companies, to propose and support policies and incentives in antimicrobial research and development in Europe. In parallel, Florence has been contributing as representative of health sciences companies innovating in AMR in a series of working groups in France which led to National structural decisions and incentives to tackle the AMR issue by the French government (Carlet’s report, Comité Stratégique de Filière – Mesure 11 focused on AMR, “feuille de route” of the French government – Nov 2016).